ensartinib + osimertinib

Ensartinib + osimertinib is an investigational combination therapy consisting of two small molecule tyrosine kinase inhibitors, each targeting distinct oncogenic drivers in non-small cell lung cancer (NSCLC). Ensartinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor approved for ALK-positive NSCLC, while osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-mutated NSCLC. This combination has been explored in cases where patients with EGFR-mutant NSCLC develop acquired resistance to osimertinib due to the emergence of ALK fusions such as EML4-ALK. The rationale for combining these agents is to simultaneously inhibit both EGFR and ALK signaling pathways, thereby overcoming resistance mechanisms and providing clinical benefit in complex molecular subtypes of NSCLC[1][2]. Clinical evidence supporting this approach comes primarily from case reports and small series; durable responses have been observed but most patients experience disease progression within several months[1][2].

Brand names

Ensacove (ensartinib)Tagrisso (osimertinib)